Literature DB >> 28523589

Alternating Acetaminophen and Ibuprofen versus Monotherapies in Improvements of Distress and Reducing Refractory Fever in Febrile Children: A Randomized Controlled Trial.

Shuanghong Luo1, Mengdong Ran2, Qiuhong Luo1, Min Shu1, Qin Guo1, Yu Zhu1, Xiaoping Xie3, Chongfan Zhang4, Chaomin Wan5.   

Abstract

BACKGROUND: No evidence can be found in the medical literature about the efficacy of alternating acetaminophen and ibuprofen treatment in children with refractory fever.
OBJECTIVE: Our objective was to assess the effect of alternating acetaminophen and ibuprofen therapy on distress and refractory fever compared with acetaminophen or ibuprofen as monotherapy in febrile children.
METHODS: A total of 474 febrile children with axillary temperature ≥38.5 °C and fever history ≤3 days in a tertiary hospital were randomly assigned to receive either (1) alternating acetaminophen and ibuprofen (acetaminophen 10 mg/kg per dose with shortest interval of 4 h and ibuprofen 10 mg/kg per dose with shortest interval of 6 h and the shortest interval between acetaminophen and ibuprofen ≥2 h; n = 158), (2) acetaminophen monotherapy (10 mg/kg per dose with shortest interval of 4 h; n = 158), or (3) ibuprofen monotherapy (10 mg/kg per dose with shortest interval of 6 h; n = 158). The mean Non-Communicating Children's Pain Checklist (NCCPC) score was measured every 4 h, and axillary temperatures were measured every 2 h.
RESULTS: In total, 471 children were included in an intention-to-treat analysis. No significant clinical or statistical difference was found in mean NCCPC score or temperature during the 24-h treatment period in all febrile children across the three groups. Although the proportion of children with refractory fever for 4 h and 6 h was significantly lower in the alternating group than in the monotherapy groups (4 h: 11.54% vs. 26.58% vs. 21.66%, respectively [p = 0.003]; 6 h: 3.85% vs. 10.13% vs. 17.83%, respectively [p < 0.001]), the mean NCCPC score of children with refractory fever for 4 or 6 h was not lower than those in either of the monotherapy groups. The number of patients who developed persistent high body temperature was consistent across all study groups.
CONCLUSIONS: Alternating acetaminophen and ibuprofen can reduce the proportion of children with refractory fever, but if one cycle of alternating therapy cannot reduce febrile distress as defined by NCCPC score, two or more cycles of alternating therapy may have minimal to no clinical efficacy in some cases. The trial was registered with the Chinese Clinical Trial Registry as ChiCTR-TRC-13003440 and the WHO Registry Network as U1111-1146-6714.

Entities:  

Keywords:  Acetaminophen; Axillary Temperature; Febrile Seizure; Ibuprofen; Monotherapy Group

Mesh:

Substances:

Year:  2017        PMID: 28523589     DOI: 10.1007/s40272-017-0237-1

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  35 in total

1.  Alternating antipyretics: is this an alternative?

Authors:  M T Del Vecchio; E R Sundel
Journal:  Pediatrics       Date:  2001-11       Impact factor: 7.124

2.  Alternating antipyretics for fever reduction in children: an unfounded practice passed down to parents from pediatricians.

Authors:  Ashley D Wright; Erica L Liebelt
Journal:  Clin Pediatr (Phila)       Date:  2007-03       Impact factor: 1.168

3.  [Antipyretics indication by pediatricians. Internet as a tool in data collections].

Authors:  Ariel Melamud; Alejandro Suwezda; Rodrigo Matamoros; Lucio Ringuelet
Journal:  Arch Argent Pediatr       Date:  2008-10       Impact factor: 0.635

Review 4.  Combined and alternating paracetamol and ibuprofen therapy for febrile children.

Authors:  Tiffany Wong; Antonia S Stang; Heather Ganshorn; Lisa Hartling; Ian K Maconochie; Anna M Thomsen; David W Johnson
Journal:  Cochrane Database Syst Rev       Date:  2013-10-30

Review 5.  Fever and antipyretic use in children.

Authors:  Janice E Sullivan; Henry C Farrar
Journal:  Pediatrics       Date:  2011-02-28       Impact factor: 7.124

6.  Preliminary validation of an observational pain checklist for persons with cognitive impairments and inability to communicate verbally.

Authors:  L M Breau; P J McGrath; C Camfield; C Rosmus; G A Finley
Journal:  Dev Med Child Neurol       Date:  2000-09       Impact factor: 5.449

7.  Psychometric properties of the non-communicating children's pain checklist-revised.

Authors:  Lynn M Breau; Patrick J McGrath; Carol S Camfield; G Allen Finley
Journal:  Pain       Date:  2002-09       Impact factor: 6.961

8.  Behaviours caregivers use to determine pain in non-verbal, cognitively impaired individuals.

Authors:  P J McGrath; C Rosmus; C Canfield; M A Campbell; A Hennigar
Journal:  Dev Med Child Neurol       Date:  1998-05       Impact factor: 5.449

9.  Over-the-counter medication use for childhood fever: a cross-sectional study of Australian parents.

Authors:  Anne Walsh; Helen Edwards; Jenny Fraser
Journal:  J Paediatr Child Health       Date:  2007-06-29       Impact factor: 1.954

10.  Thermometry in children.

Authors:  Prerna Batra; Abhijeet Saha; Moonis Mohammed Akbar Faridi
Journal:  J Emerg Trauma Shock       Date:  2012-07
View more
  3 in total

1.  Embedded 3D Printing of Novel Bespoke Soft Dosage Form Concept for Pediatrics.

Authors:  Katarzyna Rycerz; Krzysztof Adam Stepien; Marta Czapiewska; Basel T Arafat; Rober Habashy; Abdullah Isreb; Matthew Peak; Mohamed A Alhnan
Journal:  Pharmaceutics       Date:  2019-11-26       Impact factor: 6.321

Review 2.  Effects of acetaminophen and ibuprofen monotherapy in febrile children: a meta-analysis of randomized controlled trials.

Authors:  Ning Kuo; Nien-Yin Su; Sen-Kuang Hou; Yi-No Kang
Journal:  Arch Med Sci       Date:  2021-08-22       Impact factor: 3.707

3.  Risk of wheezing and asthma exacerbation in children treated with paracetamol versus ibuprofen: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Mohamed Sherbash; Luis Furuya-Kanamori; Joanne Daghfal Nader; Lukman Thalib
Journal:  BMC Pulm Med       Date:  2020-03-23       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.